The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study.
 
Tina Cascone
Honoraria - Bristol-Myers Squibb; Society for Immunotherapy of Cancer; Society for Immunotherapy of Cancer
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MedImmune (Inst)
 
William Nassib William
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Merck; Pfizer; Roche
Speakers' Bureau - Boehringer Ingelheim
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); OSI Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb; Merck
 
Annikka Weissferdt
No Relationships to Disclose
 
Heather Y. Lin
No Relationships to Disclose
 
Cheuk Hong Leung
No Relationships to Disclose
 
Brett W. Carter
No Relationships to Disclose
 
Frank V. Fossella
No Relationships to Disclose
 
Frank Mott
No Relationships to Disclose
 
Vassiliki Papadimitrakopoulou
Consulting or Advisory Role - Abbvie; Araxes Pharma; ARIAD; Arrys Therapeutics; AstraZeneca; Biothera; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Genentech; Genentech; Gritstone Bio; Janssen; Lilly; Loxo; Merck; Nektar; Novartis; Pfizer; Takeda; Tesaro; TRM Oncology
Research Funding - ACEA Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); Clovis Oncology (Inst); Guardant Health (Inst); Incyte (Inst); Janssen Oncology (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Roche; Roche
Other Relationship - Roche
 
George R. Blumenschein, Jr.
Consulting or Advisory Role - Abbvie; Adicet Bio; Amgen; ARIAD; Bayer; Bristol-Myers Squibb; Celgene; Clovis Oncology; Genentech; Merck; Novartis; Xcovery
Research Funding - Adaptimmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Exelixis; Genentech (Inst); GlaxoSmithKline (Inst); Immatics; Incyte; Kite, a Gilead company (Inst); Macrogenics (Inst); MedImmune; Merck (Inst); Novartis (Inst); Roche; Torque; Xcovery (Inst)
 
Xiuning Le
Consulting or Advisory Role - AstraZeneca; Lilly
 
Lorenzo Federico
No Relationships to Disclose
 
Edwin Roger Parra Cuentas
No Relationships to Disclose
 
Chantale Bernatchez
Stock and Other Ownership Interests - Lexicon (I)
Research Funding - EMD Serono; Idera; Iovance Biotherapeutics; MedImmune; Nektar; Pfizer
Patents, Royalties, Other Intellectual Property - Patent pending on BTLA as a marker for better CD8 T cells for adoptive immunotherapy
 
Ignacio Ivan Wistuba
Consulting or Advisory Role - AstraZeneca/MedImmune; Asuragen; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; MSD Oncology; Pfizer; Roche
Research Funding - 4D Molecular Therapeutics (Inst); Adaptimmune (Inst); Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Genentech (Inst); Guardant Health (Inst); HTG Molecular Diagnostics (Inst); Karus Therapeutics (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); OncoPlex Diagnostics (Inst); Pfizer (Inst); Silicon Biosytems (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; HTG Molecular Diagnostics; MSD Oncology; Pfizer
 
Ara A. Vaporciyan
No Relationships to Disclose
 
Don Lynn Gibbons
Stock and Other Ownership Interests - Exact Sciences; Nektar
Consulting or Advisory Role - GlaxoSmithKline; Janssen Research & Development; Sanofi
Research Funding - AstraZeneca; Janssen Research & Development; Takeda
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; BerGenBio; Takeda
 
Stephen Swisher
Travel, Accommodations, Expenses - Ethicon
 
John Heymach
Stock and Other Ownership Interests - Bio-Tree; Cardinal Spine
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; EMD Serono; Genentech; GlaxoSmithKline; Guardant Health; Hengrui Pharmaceutical; Merck; Novartis; Spectrum Pharmaceuticals
Research Funding - AstraZeneca (Inst); Spectrum Pharmaceuticals
Patents, Royalties, Other Intellectual Property - Licensing agreement between Spectrum and MD Anderson (including myself) regarding intellectual property for treatment of EGFR and HER2 exon 20 mutations
 
Boris Sepesi
No Relationships to Disclose